• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Aug 11, 2011
    Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
  • Aug 8, 2011
    Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
  • Aug 1, 2011
    Insmed Incorporated Announces Clinical Hold on ARIKACE® Phase 3 Clinical Trials
  • Jul 26, 2011
    Insmed to Host 2011 Second Quarter Earnings Conference Call
  • Jul 18, 2011
    Andrea Drucker Joins Insmed as General Counsel
  • Jun 28, 2011
    Insmed Announces its Addition to the Russell 3000® Index
  • Jun 10, 2011
    Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
  • May 10, 2011
    Insmed Announces First Quarter 2011 Financial Results
    Insmed Announces First Quarter 2011 Financial Results
  • Apr 26, 2011
    Insmed to Host 2011 First Quarter Earnings Conference Call
    Insmed to Host 2011 First Quarter Earnings Conference Call
  • Mar 21, 2011
    Insmed Regains NASDAQ Compliance
  • Mar 21, 2011
    Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
  • Mar 10, 2011
    Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
  • Mar 3, 2011
    Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication
  • Mar 2, 2011
    One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective
  • Mar 1, 2011
    Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
  • Feb 24, 2011
    Insmed to Participate on Phase III and Beyond Panel at 2011 RBC Capital Markets Healthcare Conference
  • Feb 23, 2011
    Insmed to Host Fourth Quarter and 2010 Year-End Earnings Conference Call
  • Dec 16, 2010
    NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
  • Dec 2, 2010
    Insmed Incorporated and Transave, Inc. Announce Business Combination
  • Nov 3, 2010
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
  • Oct 26, 2010
    Insmed to Host Third Quarter 2010 Conference Call
  • Aug 4, 2010
    Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2010
  • Jul 28, 2010
    Insmed to Host Second Quarter 2010 Conference Call
  • Jun 21, 2010
    Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
  • May 6, 2010
    Insmed Announces First Quarter 2010 Financial Results
  • Apr 22, 2010
    Insmed to Host First Quarter 2010 Conference Call
  • Mar 22, 2010
    Pharmaceutical Industry Veteran Nicholas LaBella Jr., MS, RPh, Joins Insmed as Chief Scientific Officer
  • Mar 15, 2010
    Insmed Announces Fourth Quarter and Full-Year 2009 Financial Results
  • Mar 4, 2010
    Insmed Regains NASDAQ Compliance
  • Mar 3, 2010
    Insmed to Host Fourth Quarter and Full-Year 2009 Conference Call
  • Nov 6, 2009
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009
  • Oct 22, 2009
    Insmed To Host Third Quarter 2009 Conference Call
  • Sep 16, 2009
    Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
  • Aug 13, 2009
    Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009
  • Jul 31, 2009
    Insmed to Host Second Quarter 2009 Conference Call
  • Jul 27, 2009
    Insmed Provides Update on Supply of IPLEX(TM)
  • Jun 30, 2009
    Insmed Announces Addition to the Russell 3000(R) Index
  • Jun 25, 2009
    Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
  • Jun 15, 2009
    Insmed CEO Resigns Due to Health Concerns
  • May 13, 2009
    Insmed Announces First Quarter 2009 Financial Results
  • May 5, 2009
    Insmed Regains NASDAQ Compliance
  • Apr 23, 2009
    Insmed to Host First Quarter 2009 Conference Call
  • Apr 22, 2009
    Insmed to Host First Quarter 2009 Conference Call
  • Mar 31, 2009
    Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
  • Mar 30, 2009
    Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
  • Mar 25, 2009
    Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
  • Mar 11, 2009
    Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
  • Mar 10, 2009
    Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
  • Feb 26, 2009
    Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
  • Feb 12, 2009
    Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Show 5102550100 per page
  • «
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy